From: Hommel, Carolyn - OC on behalf of OC GCP Questions
Sent: Friday, July 14, 2006 3:31 PM
To: **[Redacted]**
Subject: RE: Clinical Trial

Dear Mr. **[Redacted]**:

The information that you request is generally considered commercial confidential information which can not be released by FDA staff. [See 21 CFR 312.130.] You would need to confer with the sponsor of the application (typically the company developing the product) and/or any information that the sponsor places in the public domain.

Sincerely,

Carolyn Hommel
Consumer Safety Officer
Good Clinical Practice Program
Office of Science and Health Coordination
Office of the Commissioner
U.S. Food and Drug Administration (HF-34)
5600 Fishers Lane, Room 14-B17
Rockville, MD 20857

Phone: 301/827-3340
Fax: 301/827-1169

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

From: **[Redacted]**
Sent: Friday, July 14, 2006 9:19 AM
To: OC GCP Questions
Subject: Clinical Trial

Hello,

I was doing some research on **[Redacted]** injections for people with **[Redacted]** and came across a study that is in the Phase III portion of the trial. However, there was no info given. Is there any way that I can find out some information on the phase I and II outcomes? Or even phase III if it is done?

This is the reference number: **[Redacted]**

This was also given, not sure if this means anything. Study ID Numbers: **[Redacted]**

Thank you,

[Redacted]